NasdaqGS - Nasdaq Real Time Price USD

Xeris Biopharma Holdings, Inc. (XERS)

4.9000

-0.0500

(-1.01%)

At close: May 13 at 4:00:01 PM EDT

4.9000

0.00

(0.00%)

After hours: May 13 at 7:30:07 PM EDT

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major […]

Insider Monkey yesterday

XERS
-1.01%

^RUT

BLK
Xeris Biopharma Holdings First Quarter 2025 Earnings: Beats Expectations

Xeris Biopharma Holdings ( NASDAQ:XERS ) First Quarter 2025 Results Key Financial Results Revenue: US$60.1m (up 48...

Simply Wall St. 3 days ago

XERS
-1.01%
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

Xeris Biopharma Holdings Inc (XERS) reports a 48% revenue increase, raises guidance, and secures FDA approval, while navigating competitive pressures and expansion costs.

GuruFocus.com 4 days ago

XERS
-1.01%
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 days ago

XERS
-1.01%
Xeris Biopharma: Q1 Earnings Snapshot

CHICAGO (AP) — Xeris Biopharma Holdings, Inc. XERS) on Thursday reported a loss of $9.2 million in its first quarter. The Chicago-based company said it had a loss of 6 cents per share.

Associated Press Finance 5 days ago

XERS
-1.01%
Xeris Biopharma Reports Record First Quarter 2025 Financial Results

CHICAGO, May 08, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.

Business Wire 5 days ago

XERS
-1.01%
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

CHICAGO, May 01, 2025--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire 12 days ago

XERS
-1.01%
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Xeris Biopharma...

Simply Wall St. 17 days ago

XERS
-1.01%
Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?

We recently published a list of 10 Best Multibagger Penny Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Xeris Biopharma Holdings Inc. (NASDAQ:XERS) stands against other best multibagger penny stocks to buy according to billionaires. Penny stocks always seem like bargains for gaining exposure to […]

Insider Monkey 21 days ago

XERS
-1.01%
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. “John brings decades of experience and an extens

GlobeNewswire 26 days ago

XERS
-1.01%

DSGN

ANAB
Xeris Announces Changes to Its Board of Directors

CHICAGO, March 28, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris’ board to fill the vacancy. In addition,

Business Wire last month

XERS
-1.01%
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After […]

Insider Monkey last month

XERS
-1.01%
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

XERS
-1.01%

AUPH
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other stocks to invest in for a stock market game. We all have heard the phrase ‘value isn’t always visible […]

Insider Monkey last month

XERS
-1.01%
Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Key Insights The projected fair value for Xeris Biopharma Holdings is US$6.17 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. last month

XERS
-1.01%
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

CHICAGO, March 17, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract

Business Wire last month

XERS
-1.01%
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Xeris Biopharma Holdings Inc (XERS) reports robust revenue growth and strategic advancements despite market challenges.

GuruFocus.com 2 months ago

XERS
-1.01%
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

XERS
-1.01%
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

XERS
-1.01%
Xeris Biopharma: Q4 Earnings Snapshot

The Chicago-based company said it had a loss of 3 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 7 cents per share.

Associated Press Finance 2 months ago

XERS
-1.01%

Performance Overview

Return	XERS	S&P 500 (^GSPC)
YTD	+44.54%	+0.08%
1-Year	+159.26%	+12.74%
3-Year	+186.55%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

Xeris Biopharma Holdings First Quarter 2025 Earnings: Beats Expectations

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

Xeris Biopharma: Q1 Earnings Snapshot

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Xeris Announces Changes to Its Board of Directors

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Xeris Biopharma: Q4 Earnings Snapshot

Performance Overview